• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib.

作者信息

Monzonís Xavier, Arriola Edurne

机构信息

Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.

Medical Oncology Department, Hospital del Mar-CIBERONC, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain.

出版信息

J Thorac Oncol. 2019 Nov;14(11):e247-e248. doi: 10.1016/j.jtho.2019.06.013.

DOI:10.1016/j.jtho.2019.06.013
PMID:31668321
Abstract
摘要

相似文献

1
Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib.一名曾因布加替尼出现肺部毒性的患者使用劳拉替尼后出现早期肺部毒性。
J Thorac Oncol. 2019 Nov;14(11):e247-e248. doi: 10.1016/j.jtho.2019.06.013.
2
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.一名携带G1202R突变及同步发生新型R1192P ALK点突变且接受过大量治疗的肺腺癌患者对劳拉替尼产生显著反应。
J Thorac Oncol. 2018 Aug;13(8):e145-e147. doi: 10.1016/j.jtho.2018.03.017.
3
Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.布加替尼再挑战作为第五线 ALK 抑制治疗在肺癌患者中的颅内缓解。
Anticancer Drugs. 2019 Nov;30(10):1058-1060. doi: 10.1097/CAD.0000000000000800.
4
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.布加替尼和劳拉替尼：它们对非小细胞肺癌中 ALK 抑制剂的影响，重点关注耐药突变和中枢神经系统转移。
Jpn J Clin Oncol. 2021 Jan 1;51(1):37-44. doi: 10.1093/jjco/hyaa192.
5
Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib.阿来替尼和布加替尼耐药后lorlatinib 颅内治疗成功：布加替尼中枢神经系统穿透率的影响。
Thorac Cancer. 2024 Aug;15(23):1772-1775. doi: 10.1111/1759-7714.15395. Epub 2024 Jun 24.
6
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.一名对布加替尼产生获得性耐药的ALK阳性肺癌患者中存在的复合L1196M/G1202R ALK突变也导致对劳拉替尼的原发性耐药。
J Thorac Oncol. 2019 Nov;14(11):e257-e259. doi: 10.1016/j.jtho.2019.06.028.
7
Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.劳拉替尼挽救了一名先前接受过克唑替尼和高剂量布加替尼治疗的ALK阳性非小细胞肺癌患者的中枢神经系统复发。
Clin Lung Cancer. 2019 Mar;20(2):e133-e136. doi: 10.1016/j.cllc.2018.11.010. Epub 2018 Nov 29.
8
Brigatinib versus crizotinib for ALK-positive NSCLC.布加替尼与克唑替尼治疗ALK阳性非小细胞肺癌的对比
Lancet Oncol. 2018 Nov;19(11):e585. doi: 10.1016/S1470-2045(18)30741-1. Epub 2018 Oct 4.
9
Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy.携带EGFR 19del/C797S/T790M三重突变的肺腺癌对布加替尼和抗EGFR抗体联合治疗有反应。
J Thorac Oncol. 2019 May;14(5):e85-e88. doi: 10.1016/j.jtho.2019.01.015. Epub 2019 Jan 31.
10
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.洛拉替尼治疗 ALK 阳性非小细胞肺癌患者的疗效：一项全球性 2 期研究结果。
Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6.

引用本文的文献

1
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.洛拉替尼治疗 ALK+晚期非小细胞肺癌不良事件管理的专家共识。
Clin Drug Investig. 2024 Aug;44(8):553-576. doi: 10.1007/s40261-024-01379-7. Epub 2024 Jul 31.
2
Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report.阿来替尼诱发肺炎后使用劳拉替尼：一例报告
JTO Clin Res Rep. 2023 Oct 19;5(2):100591. doi: 10.1016/j.jtocrr.2023.100591. eCollection 2024 Feb.
3
A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
ALK 阳性非小细胞肺癌患者在服用阿来替尼后发生间质性肺病，使用克唑替尼治疗后有效。
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023 Oct 8;52(5):583-587. doi: 10.3724/zdxbyxb-2023-0319.
4
[Early Onset Pulmonary Events and Management Strategies during the Treatment of 
ALK Positive NSCLC Patients with Brigatinib].[布加替尼治疗ALK阳性非小细胞肺癌患者期间的早期肺部事件及管理策略]
Zhongguo Fei Ai Za Zhi. 2023 Apr 20;26(4):281-290. doi: 10.3779/j.issn.1009-3419.2023.101.12.
5
Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta-analysis.不同间变性淋巴瘤激酶酪氨酸激酶抑制剂方案治疗后肺炎的发生率：一项更新的系统评价和荟萃分析。
Cancer Med. 2023 Jul;12(13):13873-13884. doi: 10.1002/cam4.5913. Epub 2023 Apr 5.
6
An Unusual Case of Lorlatinib-Induced Pneumonitis: A Case Report.一例洛拉替尼诱发肺炎的罕见病例：病例报告
Case Rep Oncol. 2022 Mar 14;15(1):225-230. doi: 10.1159/000520158. eCollection 2022 Jan-Apr.